Biosurfactants are biomolecules with surface active properties, produced mostly by microbes and which offer potential commercial applications. Chemically, biosurfactants can be either glycopeptides, lipopeptides/lipoproteins, fatty acids, phospholipids or neutral lipids, particulate extracellular membranes or polysaccharides conjugated with proteins. Despite of varying chemical composition and molecular weights, all biosurfactants possess the characteristic properties of surface activity, like, lowering surface energy, amphiphilic behaviour towards organic and inorganic solvents. These biomolecules also increase the permeability of and disrupt biomembranes, disrupt biofilms, bind proteins, with bacteriostatic or bactericidal effects. Bacteria may show short-term or long-term tolerance to these effects. In dentistry, biosurfactants offer a vast scope in development and potential use due to their anti-inflammatory as well as antiadhesive activity, immunomodulatory action, antimicrobial applications (antiviral, antitubercular, antibacterial, antifungal), antineoplastic activity and novel uses in gene therapy and drug delivery. The rising death toll in the ongoing COVID-19 crisis is also pushing towards novel avenues of research. Current management of patients is mainly symptomatic but biosurfactants can potentially be both preventive and even curative agents. As the ongoing global environmental, economic and healthcare crises continue to develop, biosurfactants offer hope. Successful commercial use will depend on how well the scientific community and industry leaders clear the bottlenecks in production and supply chain optimisation.